Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.87), $0.61 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.